Astrazeneca pledges to fight patent ruling
Shares in drugs giant AstraZeneca today fell 4% after an American court ruled patents covering a key heart drug were invalid.
The court found that patents on Toprol XL – which were due to expire in September 2007 – were “unenforceable” in a case against rival drugmakers.





